Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology | Infections and Infectious Diseases | Family Medicine
 Disease Category: Irritable Bowel Syndrome (IBS)
Location: United States, CA

Trial Information

Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS) needed for a clinical research trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study To Access The Efficacy And Safety Of Three Different Doses (275, 550, and 1100 MG) Of Rifaximin Administered BID For Either Two Or Four Weeks in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Study visits include a screening visit and 8 office visits over 16 weeks.

Major Inclusion Criteria:
  • Female or Male at least 18 years old
  • Irritable Bowel Syndrome presenting with diarrhea associated IBS symptoms
As part of the study, you will receive at no cost:
  • Study-related medical care and exams
  • Study-related medication
  • Compensation up to $300.00 for time and travel

Call today if you would like to learn more about this study and to find out if you qualify.

Silvia Sanchez, Patient Recruitment Coordinator
Anaheim Clinical Trials (ACT)
1211 W. La Palma Ave., Suite 602
Anaheim, CA 92801
Phone: 714-778-1309 x.227
Fax: 714-778-0667
Email: info@advancedtrials.com

View Map

Research Center Information: Anaheim Clinical Trials (ACT)

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.